Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07166263 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer

StatusRecruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened
    • Start date changed from estimate of Nov 2025 to Oct 16, 2025
    • Eligibility criteria expanded, about 16 words
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will evaluate the safety and efficacy of NK510 in the treatment of relapsed and refractory advanced gastric cancer and colorectal cancer.NK510 will be administered by intravenous infusion for systemic therapy and intraperitoneal perfusion therapy. The safety and efficacy of this treatment will be evaluated.
Trial Details
NCT Number NCT07166263
Lead Sponsor Base Therapeutics (Shanghai) Co., Ltd.
Conditions
(from sponsor)		 Gastric Cancer (GC), Colorectal Cancer
Related terms Colorectal Neoplasms, Stomach Neoplasms
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov